Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population.

M Jasek, M Wagner, M Sobczynski, D Wolowiec, K Kuliczkowski, D Woszczyk, M Kielbinski, P Kusnierczyk, I Frydecka, L Karabon

Journal: Tissue antigens 2016;86(4):279-84

PMID: 26268376

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

The association of single-nucleotide polymorphisms (SNPs) of B-cell activating factor (BAFF)/a proliferation-inducing ligand (APRIL) system with B-cell chronic lymphocytic leukemia (B-CLL) have been suggested, therefore, we investigated 20 SNPs of BAFF, APRIL, BAFF-R, transmembrane activator and calcium modulator and cyclophilin-ligand interactor (TACI), B-cell maturation antigen (BCMA) genes and the risk and outcome of B-CLL in 187 patients and 296 healthy subjects as well as ligand-receptor gene × gene interactions. Although the obtained P-values for all 20 SNPs did not reach statistical significance for this study (α = 0.003), the high value of the global chi-squared statistic (χ(2) df = 38 = 52.65; P = 0.0586), and obtained values of odds ratio indicate that rs9514828 (BAFF), rs3803800 (APRIL) and rs4985726 (TACI) may be associated with the risk of B-CLL. We observed that the B-CLL patients with the genotype rs9514828CT/rs11570136AA were diagnosed with the disease 12 years later than the whole group of patients in this study.

Address: Laboratory of Immunogenetics and Tissue Immunology, Department of Clinical Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.; Department of Genomics, Faculty of Biotechnology, University of Wrocław, Wroclaw, Poland.; Department of Hematology, Neoplastic Diseases & Bone Marrow Transplantation, Medical University, Wroclaw, Poland.; Department of Hematology, State Hospital, Opole, Poland.; Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Science, Wroclaw, Poland.; Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Science, Wroclaw, Poland.; Department of Clinical Urology, Wroclaw Medical University, Wroclaw, Poland.

DOI: 10.1111/tan.12641

Link outs

Free resources

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-3697

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-TNFRSF17...

Subscription / membership required

Full Text Sources:

MeSH Terms: Aged, B-Cell Activating Factor, B-Cell Activation Factor Receptor, B-Cell Maturation Antigen, B-Lymphocytes, Case-Control Studies, Female, Gene Expression, Genetic Predisposition to Disease, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Odds Ratio, Poland, Polymorphism, Single Nucleotide, Risk Factors, Transmembrane Activator and CAML Interactor Protein, Tumor Necrosis Factor Ligand Superfamily Member 13